Rodríguez de Vera-Gómez, PabloPiñar-Gutiérrez, AnaGuerrero-Vázquez, RaquelBellido, VirginiaMorales-Portillo, CristóbalSancho-Márquez, María PilarEspejo-García, PabloGros-Herguido, NoeliaLópez-Gallardo, GemaMartínez-Brocca, María AsunciónSoto-Moreno, Alfonso2023-05-032023-05-032022-11-04http://hdl.handle.net/10668/20176The aim of this study is to investigate in depth diabetes mellitus associated with immune checkpoint inhibitors (DM-ICIs) by analysing a case series. We also evaluated the clinical impact of flash glucose monitoring (FGM) systems in the management of this entity. We conducted an observational cohort study of DM-ICIs diagnosed in two hospitals in Seville (Spain). Patients with a new diagnosis of diabetes mellitus (DM) or with sudden worsening of preexisting DM after starting treatment with ICIs, with a random 5 hour-postprandial C-peptide value of A total of 7 cases were identified, mostly males (n = 6; 85.7%), with a mean age of 64.9 years. The mean glycated hemoglobin (HbA1c) upon diagnosis was 8.1%, with diabetic ketoacidosis (DKA) observed in 6 cases (85.7%). Subcutaneous flash glucose monitoring (FGM) systems were used in six cases, with a mean follow-up period of 42.7 weeks. During the first 90 days of use, mean average glucose was 167.5 mg/dL, with a coefficient of variation (CV) of 34.6%. The mean time in the range 70-180 mg/dL (TIR) was 59.7%, with a mean time above range (TAR) 181-250 mg/dL of 27.8% and a mean TAR > 250 mg/dL of 10.2%. The mean time below range (TBR) 54-69 mg/dL was 2%, while the mean TBR 250 mg/dL of 10.2%. The mean time below range (TBR) 54-69 mg/dL was 2%, while the mean TBR 250 mg/dL (16.3% to 7.7%, p = 0.09), mean TBR 54-69 mg/dL (5.2% to 2%, p = 0.16), and mean TBR DM-ICI is recognised by a state of sudden-onset insulinopenia, often associated with DKA. The use of FGM systems may be a valid option for the effective management of DM-ICIs and for the prevention of severe hyperglycaemic and hypoglycaemic episodes in this condition.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/MaleHumansMiddle AgedAgedFemaleBlood Glucose Self-MonitoringBlood GlucoseImmune Checkpoint InhibitorsCohort StudiesDiabetic KetoacidosisDiabetes Mellitusresearch article36387939open access10.1155/2022/45086332314-6753PMC9652069https://downloads.hindawi.com/journals/jdr/2022/4508633.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652069/pdf